TM Owner GSK
Menveo 0.5ml Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Menveo (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine), 0.5 mL per dose, is a vaccine currently marketed by GSK that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
- In the US it is approved for people aged 2 months through 55 years; infants receive a multi-dose primary series starting at 2 months, while people aged 2 years and older usually need only a single dose, with a booster recommended for those who remain at continued risk, such as during outbreaks or with certain immune conditions.
- Menveo does not protect against serogroup B disease, which needs a separate vaccine.
- It is given only by intramuscular injection in a clinic or hospital setting.
Side Effects
- Menveo carries no boxed warning.
- In infants receiving the multi-dose series, the most frequently reported reactions, each affecting more than 1 in 10 recipients, are irritability, sleepiness, persistent crying, loss of appetite, and tenderness or redness at the injection site.
- In children, adolescents and adults, injection-site pain is the most common reaction, alongside headache, muscle aches, tiredness and nausea, each affecting more than 1 in 10 people in some age groups.
- Fainting (syncope) can occur around the time of injection, so patients may be observed briefly afterwards.
- Seek urgent medical help for signs of a severe allergic reaction, such as swelling of the face or throat, breathing difficulty or hives soon after vaccination, or for unusual weakness or tingling in the weeks afterward, which could suggest Guillain-Barre syndrome.
Precautions & Warnings
- Menveo must not be given to anyone with a known severe allergic reaction to a previous dose, to any component of the vaccine, or to any other diphtheria toxoid-containing vaccine.
- People with a weakened immune system, including those with complement deficiencies or on immunosuppressive treatment, may respond less well and remain at higher risk of meningococcal disease despite vaccination.
- Guillain-Barre syndrome has been reported after other meningococcal conjugate vaccines, so any past history should be discussed with the healthcare provider beforehand.
- Premature infants should be monitored for breathing pauses (apnea) for 48 to 72 hours after the first dose.
- Menveo is given by intramuscular injection only.
- Vaccination during pregnancy or breastfeeding should be discussed with a healthcare provider, and appropriate treatment for anaphylaxis must be available at the time of vaccination.
Avoid Interactions
- Menveo can be given at the same visit as other routine childhood and adolescent vaccines, including DTaP, Tdap, IPV, hepatitis A and B, Hib, pneumococcal conjugate, MMR, MMRV and HPV vaccines, using separate syringes and injection sites.
- Tell the healthcare provider about all other vaccines and medicines being used, particularly immunosuppressive therapy, chemotherapy or long-term corticosteroids, since these can reduce the immune response to Menveo.
- People with complement deficiencies or those taking complement-inhibitor medicines such as eculizumab remain at increased risk of meningococcal disease even after vaccination and may need additional precautions or booster doses.
- There are no known food or alcohol interactions with this vaccine; always tell the provider your full vaccination and medical history before the injection.
References
Frequently Asked Questions
Menveo is a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. It is approved for people aged 2 months through 55 years in the US. It does not protect against serogroup B meningococcal disease.
A healthcare provider gives Menveo as a single intramuscular injection, usually in the thigh for infants or the upper arm for older children and adults. Infants need a multi-dose primary series starting at 2 months; people aged 2 and older usually need just one dose.
The most common side effects are pain, redness or swelling at the injection site, headache, muscle aches and tiredness. Infants often become irritable, sleepy or lose their appetite. Seek urgent help for facial swelling, trouble breathing or hives soon after the injection.
Do not have Menveo if you have had a severe allergic reaction to it, its ingredients, or another diphtheria-containing vaccine before. Tell your healthcare provider about any immune-suppressing medicines or conditions, since these can lower your response, and about any past Guillain-Barre syndrome.
Yes. Menveo can be given at the same visit as routine vaccines including DTaP, Tdap, MMR, hepatitis A and B, polio and HPV vaccines, using a separate injection site for each. Always tell the provider about every vaccine and medicine you are currently using.
No, a single dose does not guarantee lifelong protection. People who remain at ongoing risk, such as those with certain immune conditions or in outbreak settings, may need a booster dose. People with complement deficiencies can still develop meningococcal disease even after full vaccination.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
